-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent news, AI medical imaging giant Shukun Technology has submitted a prospectus to the Hong Kong Stock Exchange and intends to be listed on the Hong Kong Main Board
.
JPMorgan Chase, Bank of America Securities, and Bank of China International Securities are their joint sponsors
.
This company, which has experienced 10 rounds of financing, with a total financing of more than 2 billion yuan, quickly attracted the attention of the industry
.
In recent years, with the continuous development of AI technology, the value of AI medical imaging used for diagnosis has become increasingly prominent.
The market is in a stage of rapid growth, but the industry as a whole is still in the initial stage of core technology market transformation, and the test is the company’s technology, capital, etc.
Aspect ability
.
According to data, Sukun Technology was established in 2017.
It is an AI medical imaging platform that provides artificial intelligence medical imaging solutions for disease screening, diagnosis, and treatment selection and planning
.
At present, the company has independently developed a medical AI neural network, and currently has a variety of digital doctor products such as "digital heart", "digital brain", "digital chest", and "digital belly", providing services for heart disease, stroke, cancer and other diseases Intelligent diagnosis and treatment plan
.
In terms of revenue, due to the widespread adoption of products, the company's revenue and gross profit have shown explosive growth since 2019
.
The prospectus shows that from 2019 to the first half of 2021, the company achieved revenues of 764,000 yuan, 24.
771 million yuan, and 52.
624 million yuan respectively; in terms of gross profit, the gross profit from 2019 to the first half of 2021 was divided into 637,000 yuan and 20.
677 million yuan.
, 44.
333 million yuan
.
However, the company is not yet profitable and has incurred losses
.
This is due to the fact that most of the company's operating losses are generated from research and development expenses, sales and marketing expenses and administrative expenses
.
The prospectus shows that from 2019 to 2020, Shukun Technology will lose 91.
298 million yuan (net loss) and 129 million yuan respectively.
The net loss in the first half of this year is 87.
424 million yuan, which is a further increase from 46.
99 million yuan in the same period of the previous year.
The net loss has exceeded 300 million yuan
.
In terms of research and development, the single R&D expenditures in each period were 42.
689 million yuan, 62.
933 million yuan and 81.
188 million yuan; the company incurred sales and marketing expenses of 16.
077 million yuan, 27.
651 million yuan and 30.
907 million yuan respectively
.
It can be seen that the company's research and development expenditure and marketing expenses continue to increase
.
Due to its technological advantages, Shukun Technology has attracted the attention of capital
.
At present, Sukun Technology has completed 10 rounds of financing.
Investors include Goldman Sachs Asset Management, Chunhua Capital, Sequoia Capital China Fund, Yuanyi Capital, Huagai Capital, Wuyuan Capital, CCV Creation Partners Capital, Qiming Venture Capital, and Bank of China International , CCB International, China Reinsurance, etc.
, the total amount of financing currently exceeds 2 billion yuan
.
Which at the end of July this year, which has just completed a new round of 700 million yuan financing, investors, including Goldman Sachs, the world's largest capital and information management, Chunhua Capital, Sequoia Capital China, and so far Yi capital
.
The industry believes that AI medical imaging is of great value and can help screen and diagnose some cases.
With the continuous growth of domestic medical service demand and the increase in the penetration rate of artificial intelligence medical imaging, the AI medical imaging market will usher in a blue ocean, according to the consulting company According to Frost & Sullivan data, China's AI medical imaging market is expected to increase from 300 million yuan in 2020 to 92.
3 billion yuan in 2030, with a compound annual growth rate of 76.
7%
.
In the face of the vast market, the layout of enterprises has also sprung up like bamboo shoots after a rain
.
In addition to Shukun Technology, since 2021, Keya's Ark, Inference Technology, Airdoc Yingpu Technology, etc.
have also chosen to list in Hong Kong
.
It is foreseeable that in the future on the AI medical imaging track, the competition between companies will be more intense
.
.
JPMorgan Chase, Bank of America Securities, and Bank of China International Securities are their joint sponsors
.
This company, which has experienced 10 rounds of financing, with a total financing of more than 2 billion yuan, quickly attracted the attention of the industry
.
In recent years, with the continuous development of AI technology, the value of AI medical imaging used for diagnosis has become increasingly prominent.
The market is in a stage of rapid growth, but the industry as a whole is still in the initial stage of core technology market transformation, and the test is the company’s technology, capital, etc.
Aspect ability
.
According to data, Sukun Technology was established in 2017.
It is an AI medical imaging platform that provides artificial intelligence medical imaging solutions for disease screening, diagnosis, and treatment selection and planning
.
At present, the company has independently developed a medical AI neural network, and currently has a variety of digital doctor products such as "digital heart", "digital brain", "digital chest", and "digital belly", providing services for heart disease, stroke, cancer and other diseases Intelligent diagnosis and treatment plan
.
In terms of revenue, due to the widespread adoption of products, the company's revenue and gross profit have shown explosive growth since 2019
.
The prospectus shows that from 2019 to the first half of 2021, the company achieved revenues of 764,000 yuan, 24.
771 million yuan, and 52.
624 million yuan respectively; in terms of gross profit, the gross profit from 2019 to the first half of 2021 was divided into 637,000 yuan and 20.
677 million yuan.
, 44.
333 million yuan
.
However, the company is not yet profitable and has incurred losses
.
This is due to the fact that most of the company's operating losses are generated from research and development expenses, sales and marketing expenses and administrative expenses
.
The prospectus shows that from 2019 to 2020, Shukun Technology will lose 91.
298 million yuan (net loss) and 129 million yuan respectively.
The net loss in the first half of this year is 87.
424 million yuan, which is a further increase from 46.
99 million yuan in the same period of the previous year.
The net loss has exceeded 300 million yuan
.
In terms of research and development, the single R&D expenditures in each period were 42.
689 million yuan, 62.
933 million yuan and 81.
188 million yuan; the company incurred sales and marketing expenses of 16.
077 million yuan, 27.
651 million yuan and 30.
907 million yuan respectively
.
It can be seen that the company's research and development expenditure and marketing expenses continue to increase
.
Due to its technological advantages, Shukun Technology has attracted the attention of capital
.
At present, Sukun Technology has completed 10 rounds of financing.
Investors include Goldman Sachs Asset Management, Chunhua Capital, Sequoia Capital China Fund, Yuanyi Capital, Huagai Capital, Wuyuan Capital, CCV Creation Partners Capital, Qiming Venture Capital, and Bank of China International , CCB International, China Reinsurance, etc.
, the total amount of financing currently exceeds 2 billion yuan
.
Which at the end of July this year, which has just completed a new round of 700 million yuan financing, investors, including Goldman Sachs, the world's largest capital and information management, Chunhua Capital, Sequoia Capital China, and so far Yi capital
.
The industry believes that AI medical imaging is of great value and can help screen and diagnose some cases.
With the continuous growth of domestic medical service demand and the increase in the penetration rate of artificial intelligence medical imaging, the AI medical imaging market will usher in a blue ocean, according to the consulting company According to Frost & Sullivan data, China's AI medical imaging market is expected to increase from 300 million yuan in 2020 to 92.
3 billion yuan in 2030, with a compound annual growth rate of 76.
7%
.
In the face of the vast market, the layout of enterprises has also sprung up like bamboo shoots after a rain
.
In addition to Shukun Technology, since 2021, Keya's Ark, Inference Technology, Airdoc Yingpu Technology, etc.
have also chosen to list in Hong Kong
.
It is foreseeable that in the future on the AI medical imaging track, the competition between companies will be more intense
.
